EMERGENT BIOSOLUTIONS INC. Contract with Customer, Liability, Noncurrent
EMERGENT BIOSOLUTIONS INC. (EBS) had Contract with Customer, Liability, Noncurrent of $5.90 million as of 2022-03-31, per its 10-Q filed 2022-04-29.
Discontinued › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent › Deferred Revenue, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2022-04-29
- 2022-03-31: Contract with Customer, Liability, Noncurrent $5.90M.
- 2021-12-31: Contract with Customer, Liability, Noncurrent $4.70M.
- 2021-09-30: Contract with Customer, Liability, Noncurrent $45.30M.
- 2021-06-30: Contract with Customer, Liability, Noncurrent $48.90M.
| Period end | Contract with Customer, Liability, Noncurrent | Contract with Customer, Liability, Noncurrent as first filed |
|---|---|---|
| 2022-03-31 | $5.90M 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $4.70M 10-Q · filed 2022-04-29 | |
| 2021-09-30 | $45.30M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $48.90M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $52.50M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $55.50M 10-K · filed 2022-02-25 | |
| 2020-09-30 | $60.40M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $85.30M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $85.00M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $85.60M 10-K · filed 2021-02-19 | |
| 2019-09-30 | $81.60M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $77.00M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $64.70M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $62.50M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $65.34M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | $63.26M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $59.37M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $17.30M 10-K · filed 2019-02-22 | $17.26M 10-Q · filed 2018-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |